← Leaderboards
Monica Andrea Serban
Promiliad Biopharma, Inc.
$1,744,956
Attributed
$1,744,956
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $751.1K · FY2018–21$1M$750K$500K$250K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$1,744,956 · 2
By mechanism
R42$1,447,131 · 1
R41$297,825 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Formulation”
- Matthew Johnson · Duke University$56,071,536
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jay Evans · University Of Montana$27,950,292
- Kristin Aillon · Midwest Research Institute$24,965,877
Research focus
FormulationGrowthEffectivenessEtiologyDropsGeneral PopulationDoseEar InfectionDiabetic PatientEffective TherapyAnti-Bacterial AgentsBiomaterial CompatibilityDrug Delivery SystemsFundingAntibioticsDependenceAffectCostBacterial Antibiotic ResistanceCollaborationsAnimal ModelDoctor Of PhilosophyBaseHealth Care Costs
Grant awards (3)
Single application thixotropic antibiotic delivery systems for otitis externa$696,062
R42 · FY2021 · DC · contact PI
Single application thixotropic antibiotic delivery systems for otitis externa$751,069
R42 · FY2020 · DC · contact PI
Single application thixotropic antibiotic delivery systems for otitis externa$297,825
R41 · FY2018 · DC · contact PI